<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02587169</url>
  </required_header>
  <id_info>
    <org_study_id>EC10-150 RETRONEO</org_study_id>
    <secondary_id>2011-002368-26</secondary_id>
    <secondary_id>GEIS-27</secondary_id>
    <nct_id>NCT02587169</nct_id>
  </id_info>
  <brief_title>Trial of Nilotinib and Adriamycin as Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum</brief_title>
  <acronym>GEIS-27</acronym>
  <official_title>GEIS-27: Phase I/II Multicenter and Prospective Trial of Nilotinib and Adriamycin as Neoadjuvant Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Broto, Javier Martín, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Broto, Javier Martín, M.D.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I/II multicenter and prospective trial of nilotinib and adriamycin as neoadjuvant
      treatment in liposarcomas and leiomyosarcomas of retroperitoneum.

      The main objective of this study is to improve relapse-free survival (RFS)and overall
      survival (OS) decreasing from 50% to 30% the relapse percentage at 5 years in patients with
      resected sarcoma of retroperitoneum.

      Secondary objectives include the analysis of antitumoral activity through response rate
      (RECIST and tissular changes), the assessment of positive correlation between biomarkers and
      clinical results, the study of long term overall survival, and the analysis of the safety
      profile of the nilotinib-adriamycin combination.

      The trial hypothesis is that the nilotinib-adriamycin combination is synergistic and
      therefore better response results are expected (from 20% as P0 to 40% as P1). The study seeks
      to find a positive correlation between biomarkers and clinical results in retroperitoneal
      liposarcoma and leiomyosarcoma treated with the mentioned combination.

      The study involves the participation of 20 hospitals of the Spanish Sarcoma Group (GEIS). The
      treatment consists of 4 neoadjuvant cycles of nilotinib-adriamycin on patients with
      resectable retroperitoneal sarcoma. The research comprises a robust translational study as
      well as histological and radiological reviews.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The nilotinib-adriamycin combination will be given in 4 cycles of 21 days. In each cycle,
      nilotinib will be administered at fixed dose of 400 mg/12h orally during 6 consecutive days
      (1-6) and endovenous adriamycin (20 minutes) on day 5 at three levels (in phase I, dosage of
      60 mg/m2, 65 mg/m2, and 75 mg/m2 will be tested to determine the recommended dose for phase
      II).

      Phase I includes patients with retroperitoneal liposarcoma, retroperitoneal leiomyosarcoma
      and chondrosarcoma. Phase II is focused on retroperitoneal liposarcoma and leiomyosarcoma
      only.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse-free survival (RFS) at 5 years</measure>
    <time_frame>5 years</time_frame>
    <description>The main goal of the study is to improve relapse-free survival (RFS) and overall survival (OS) decreasing from 50% to 30% the percentage of relapse at 5 years in patients with resected retroperitoneal sarcoma.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) (confirmed complete response [CR] and partial response [PR])</measure>
    <time_frame>Baseline and at 4 months</time_frame>
    <description>To determine the objective response rate (ORR) (confirmed complete response [CR] and partial response [PR]) using RECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>100 months</time_frame>
    <description>Overall survival measured from treatment start date until date of death, whichever the cause, assessed up to 100 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>4 months</time_frame>
    <description>Number and type of adverse events according to CTCAE 4.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Retroperitoneal Liposarcoma</condition>
  <condition>Retroperitoneal Leiomyosarcoma</condition>
  <condition>Chondrosarcoma</condition>
  <arm_group>
    <arm_group_label>Nilotinib-adriamycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The nilotinib-adriamycin combination will be given in 4 cycles of 21 days. In each cycle, nilotinib will be administered at fixed dose of 400 mg/12h orally during 6 consecutive days (1-6) and endovenous adriamycin (20 minutes) on day 5 at three levels (in phase I, dosage of 60 mg/m2, 65 mg/m2, and 75 mg/m2 will be tested to determine the recommended dose for phase II).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nilotinib-adriamycin</intervention_name>
    <description>The nilotinib-adriamycin combination will be given in 4 cycles of 21 days. In each cycle, nilotinib will be administered at fixed dose of 400 mg/12h orally during 6 consecutive days (1-6) and endovenous adriamycin (20 minutes) on day 5 at three levels (in phase I, dosage of 60 mg/m2, 65 mg/m2, and 75 mg/m2 will be tested to determine the recommended dose for phase II).</description>
    <arm_group_label>Nilotinib-adriamycin</arm_group_label>
    <other_name>Nilotinib Tasigna</other_name>
    <other_name>Doxorubicin hydrochloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histological diagnosis of well differentiated liposarcoma,
             dedifferentiated liposarcoma or primary leiomyosarcoma of retroperitoneum and
             resectable. In phase I the study will recruit patients with high-grade chondrosarcoma
             of non-mesenchymal type.

          -  Age: 18-70 years.

          -  Measurable disease, according to RECIST criteria.

          -  Functional status: 0-1 (ECOG).

          -  Baseline medullar function (hemoglobin &gt; 10 g/dL, leukocytes ≥ 3.000/mm3, RAN≥ 1,5 x
             109 /l, granulocytes ≥ 1.500/mm3, platelets ≥ 100.000/mm3). Patients with alteration
             of transaminases ≤ 2.5 times the normal limits, bilirubin total ≤ LSN, CPK≤ 2.5 times
             the normal limits, alkaline phosphatase ≤ 2.5 times more the normal limits or
             creatinine values ≤ 1.6 mg/dL, are accepted.

          -  Cardiac function (LVEF) normal, considering the normal ranges of the institution.

          -  The patient must voluntarily sign the informed consent before any trial test, knowing
             that he/she can leave the trial at any time, without any consequence for his/her
             posterior medical attention.

          -  Patients in fertile age (both male and female) must use an effective contraceptive
             method before the entry in the study and during the trial. Moreover, women must
             maintain contraceptive measures up to 5 months after the treatment. Pregnancy must be
             ruled out though urine test (negative pregnancy test) for study enrolment.

        Exclusion Criteria:

          -  Patients having received previous chemotherapy.

          -  Patient having been irradiated on the tumoral disease.

          -  Functional status &gt; 1 (ECOG).

          -  Metastasis in any location.

          -  Bilirubin values over the normal level. Creatinine over 1.6 mg/dL.

          -  History of another oncological disease except basalioma or in situ cervical carcinoma
             adequately treated.

          -  Serious cardiovascular diseases (dyspnea &gt;= 2 NYHA, ie.)

          -  Systemic pathologies limiting survival to less than 2 years, limiting patient
             availability, or those that, by clinical judgement, may interfere significantly with
             treatment toxicity.

          -  Bacterial, viral, or uncontrolled mycotic infectious diseases.

          -  Pregnant or lactating patients.

          -  Psychological, family, sociological or geographical situations not allowing protocol
             fulfilment or informed consent signature.

          -  Patients currently involved in other clinical trials receiving any other agent under
             investigation.

          -  Patient having participated in a clinical trial and/or having received an agent under
             investigation in the 30 days prior to enrolment.

          -  Patients requiring treatments with prolongation of QT interval as amiodarone,
             disopyramide, procainamide, quinidine, and sotalol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javier Martín, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Spanish Sarcoma Group (GEIS)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patricio J. Ledesma, BEng</last_name>
    <phone>+34 648414261</phone>
    <email>pledesma@sofpromed.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Santiago Blasco, BSc</last_name>
    <phone>+34 971439900</phone>
    <email>registros@sofpromed.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitari Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Balearic Islands</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Martín, MD, PhD</last_name>
      <phone>+34 871205705</phone>
      <email>javier.martin@ssib.es</email>
    </contact>
    <investigator>
      <last_name>Javier Martín, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Cristina</name>
      <address>
        <city>Badajoz</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignacio Delgado, MD</last_name>
      <email>ignadelgado@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Ignacio Delgado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trials i Pujol</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olatz Etxaniz, MD</last_name>
      <email>oetxaniz@iconcologia.net</email>
    </contact>
    <investigator>
      <last_name>Olatz Etxaniz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio López-Pousa, MD</last_name>
      <email>alopezp@santpau.cat</email>
    </contact>
    <investigator>
      <last_name>Antonio López-Pousa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Valverde, MD</last_name>
      <email>cmvalver@vhebron.net</email>
    </contact>
    <investigator>
      <last_name>Claudia Valverde, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Provincial de Castellón</name>
      <address>
        <city>Castellón</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramón de las Peñas, MD</last_name>
      <email>ramon.delaspenas@hospital2000.net</email>
    </contact>
    <investigator>
      <last_name>Ramón de las Peñas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>La Laguna</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josefina Cruz, MD</last_name>
      <email>jcruzjurado@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Josefina Cruz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Asistencial Universitario de León</name>
      <address>
        <city>León</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Miguel de Sande, MD</last_name>
      <email>lmgdesande@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Luis Miguel de Sande, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Cubedo, MD</last_name>
      <email>rcubedo@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ricardo Cubedo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrés Redondo, MD</last_name>
      <email>aredondo12@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Andrés Redondo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mª Ángeles Vaz, MD</last_name>
      <email>mavaz3@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Mª Ángeles Vaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Arrixaca</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerónimo Martínez, MD</last_name>
      <email>jeronimo@seom.org</email>
    </contact>
    <investigator>
      <last_name>Jerónimo Martínez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Navarra</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nuria Láinez, MD</last_name>
      <email>nuria.lainez.milagro@cfnavarra.es</email>
    </contact>
    <investigator>
      <last_name>Nuria Láinez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana de Juan, MD</last_name>
      <email>ajuan@humv.es</email>
    </contact>
    <investigator>
      <last_name>Ana de Juan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yolanda Vidal, MD</last_name>
      <email>yvidalinsua@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Yolanda Vidal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pilar Sancho, MD</last_name>
      <email>sanchomarquez@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Pilar Sancho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Salud</name>
      <address>
        <city>Toledo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Medina, MD</last_name>
      <email>boladiez39@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Javier Medina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncología</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Lavernia, MD</last_name>
      <email>javilavernia@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Javier Lavernia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Xeral Cies</name>
      <address>
        <city>Vigo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Antonio Carrasco, MD</last_name>
      <email>juan.antonio.carrasco.alvarez@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Juan Antonio Carrasco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Martínez-Trufero, MD</last_name>
      <email>jmtrufero@seom.org</email>
    </contact>
    <investigator>
      <last_name>Javier Martínez-Trufero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.grupogeis.org</url>
    <description>Spanish Sarcoma Group (GEIS)</description>
  </link>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2013</study_first_submitted>
  <study_first_submitted_qc>October 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2015</study_first_posted>
  <last_update_submitted>October 23, 2015</last_update_submitted>
  <last_update_submitted_qc>October 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>liposarcoma</keyword>
  <keyword>leiomyosarcoma</keyword>
  <keyword>retroperitoneum</keyword>
  <keyword>chondrosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyosarcoma</mesh_term>
    <mesh_term>Liposarcoma</mesh_term>
    <mesh_term>Chondrosarcoma</mesh_term>
    <mesh_term>Retroperitoneal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

